PF-232798

• Description :

  PF-232798 is an orally active CCR5 antagonist with anti-HIV effects[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  CCR; HIV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; GPCR/G Protein; Immunology/Inflammation

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/pf-232798.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CC1=NC(CN(CC2)C(C(C)C)=O)=C2N1[C@H]3C[C@]4([H])N([C@](CC4)([H])C3)CC[C@@H](C5=CC(F)=CC=C5)NC(C)=O

• Molecular Formula :

  C29H40FN5O2

• Molecular Weight :

  509.66

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

• References & Citations :

  [1]Ya Zhu, et al. Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5. Acta Pharmacol Sin. 2019 Apr;40 (4) :563-568.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [849753-15-7]